Protective immunity to diseases preventable by routine vaccination is lost over time following allogeneic and autologous blood and marrow transplantation. Adoptive transfer of immunity from donors to recipients after allogeneic transplantation is not sufficient to prevent this decline. Systematic reimmunization is necessary at appropriate time intervals following transplantation to re-establish immunity. Response to vaccination depends upon the type of transplant, the source of cells, the immune status of the patient, and the vaccine being used. While inactivated or subunit vaccines are safe in all transplant recipients, live vaccines are generally contraindicated. Reimmunization practices vary widely amongst transplant centers. This comprehensive review summarizes published data on post-transplant vaccination, and based upon these, suggests guidelines which may be used as a framework for development of reimmunization protocols. Keywords: allogeneic bone marrow transplantation; autologous bone marrow transplantation; hematopoietic stem cell transplantation; immunization; vaccination Passive immunization consists of the administration of antibody-containing immunoglobulin preparations to provide temporary protection. Active immunization refers to the administration of a vaccine or a toxoid and is analogous to vaccination.
Passive immunization consists of the administration of antibody-containing immunoglobulin preparations to provide temporary protection. Active immunization refers to the administration of a vaccine or a toxoid and is analogous to vaccination. 1 Vaccines available for routine use in children include diphtheria-pertussis-tetanus (DPT), trivalent polio, measles-mumps-rubella (MMR), Haemophilus influenzae type b (Hib), hepatitis B and tuberculosis (BCG). Adult vaccines include diphtheria-tetanus (DT), hepatitis B, influenza virus and pneumococcus. The use of meningococcal, hepatitis A and varicella vaccines is increasing. A number of other vaccines are also available for special circumstances. 1 Most allogeneic and a large proportion of autologous bone marrow transplant recipients lose their immunity to poliovirus, tetanus, diphtheria and measles after transplantation. [2] [3] [4] [5] [6] [7] [8] Additionally, transplant recipients are at increased risk of developing infections with organisms such as H. influenzae and Streptococcus pneumoniae for which vaccines are available. [9] [10] [11] Because of these reasons, it is essential to reimmunize peripheral blood stem cell (PBSCT) or bone marrow transplant (BMT) recipients at appropriate times following transplantation.
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Current practice
Systematic post-transplant reimmunization is a relatively neglected area. 12, 14 A survey of reimmunization protocols in Europe found wide variations in practice. 12 Tetanus toxoid vaccination was the most common practice, with 65% of the surveyed centers administering this to allograft recipients, and 37% to autograft recipients. On the other hand, pertussis vaccination was the least common practice, with only one center using this. 12 A survey of 45 North American transplant centers affiliated with the National Marrow Donor Program 14 showed that 97% of centers allografting patients under the age of 7 years and 88% of those allografting patients aged 7 years or older gave either the DPT or the DT vaccine, whereas 77% and 58%, respectively, used the Hib conjugate vaccine. Inactivated poliovirus and MMR vaccines were given by 94% and 94% of the centers, respectively, to patients younger than 7, and by 73% and 70%, respectively, to the older age group. Few centers reported using multiple doses, and the number of different schedules reported for specific vaccines varied widely. 14 
Principles of vaccinating transplant recipients
Immune reconstitution after BMT follows a general pattern developing from immature to mature immune functions. [15] [16] [17] [18] Immune reactivity during the first month post-transplant is very low. Cytotoxic and phagocytic functions recover by day 100, but the more specialized functions of T and B lymphocytes may remain impaired for a year or even longer. After a period of time, the various components of the immune systems of most healthy marrow recipients begin to work synchronously, whereas the immune systems of patients with chronic graftversus-host disease (GVHD) remain suppressed.
An important factor which needs to be taken into account while considering vaccination after transplantation is the patient's immune status. Antibody response to Hib vaccination has been found to be poor in human immunodefi-638 Table 1 Patients who should not be considered eligible for live vaccination after marrow or blood stem cell transplantation All autograft recipients for 2 years All allograft recipients for 2 years
Immunosuppressive therapy
Active chronic graft-versus-host disease Recurrent malignancy ciency virus (HIV)-infected patients with absolute CD4 counts of Ͻ100 × 10 6 /l. 19 Inactive, subunit or recombinant vaccines may simply be ineffective in transplant recipients, whereas live attenuated vaccines may be dangerous in immunocompromised patients. However, no data are available correlating the immune status with response to vaccination in transplant recipients. Table 1 shows the circumstances under which transplanted patients are likely to be immunocompromised for the purpose of live vaccination. If there is any question about a patient's immune recovery, measuring the CD4 count and serum immunoglobulin levels may provide useful information.
Preliminary data suggest that immune reconstitution is faster for autologous 20 as well as allogeneic 21 PBSCT compared with BMT. Because of this and the significantly larger inoculum of cells infused during PBSCT, it is possible that PBSCT recipients may have an earlier and a better response to vaccines. 22 However, the majority of the data available so far on post-transplant immunization have been gathered on recipients of marrow grafts, and it is probably reasonable to immunize PBSCT recipients in the same way as BMT recipients until more data become available. Additionally, the type of graft (allogeneic or autologous), graft manipulation (CD34 + selection or T cell depletion), the extent of HLA compatibility (matched or mismatched), and the underlying disease are also likely to affect immune recovery. 16 Table 2 lists live vaccines that are usually contraindicated in immunocompromised patients. Occastionally, it may be necessary to use live vaccines relatively early after the transplant. Under such circumstances, the potential risks and benefits must be weighed carefully. Spreadable live vaccines such as oral polio should be avoided in close contact of immunosuppressed patients. Table 3 shows a potential vaccination schedule for transplant recipients. These guidelines are based upon standard recommended immunization schedules for normal children and adolescents, 23, 24 and published data on individual vaccines in transplant recipients. Although Table 3 shows set intervals for immunization, a certain amount of flexibility including combining different vaccines on a single visit is likely to improve compliance and coverage as has been observed with normal adolescents. 23 Although early revaccination has not been studied systematically, administration of any vaccine within 3-4 months of transplantation may be of limited use because of inadequate immune reconstitution.
Individual vaccines
Diphtheria toxoid
Diphtheria has recently emerged as a problem in a number of countries where immunization coverage has been high. These outbreaks have been characterized by high fatality rates, a high proportion of cases in adults, and an increased incidence of complications underscoring the need for reimmunization.
Immunity to diphtheria is lost over a period of time. Lum et al 2 showed that while antibodies to diphtheria toxoid were present in all patients within the first 100 days after allografting, only two-thirds of normal long-term survivors with immune donors had antibodies. This reduced further to 40% among patients with chronic GVHD who were transplanted from immune donors. 2 Parkkali et al 25 showed that only six of 11 patients still had immunity against diphtheria a year after allogeneic BMT, with antitoxin levels that were barely protective.
Chronic GVHD patients had an impaired cellular immune response to dipheria toxoid when vaccinated 4 months after BMT. 26 Whether this inadequate response was the result of early vaccination or the presence of chronic GVHD is unknown because the other studies have employed late vaccination. Multiple doses of diphtheria toxoid 2-6 years after allogeneic BMT resulted in adequate immune response in thalassemia patients without chronic GVHD. 27 Multiple doses of diphtheria toxoid resulted in adequate immune response in children autografted using marrow depleted of B lymphocytes 38-54 months after BMT. 5 Vaccination starting a year after transplantation has been recommended 12,28 but has not been systematically evaluated.
Haemophilus influenzae
Haemophilis influenzae accounts for a significant proportion of pulmonary infections in long-term transplant survivors including those on prophylactic penicillin. 10, 29 However, unlike pneumococci, almost all severe disease is related to one capsular serotype (type b), and the Haemophilus influenzae b (Hib) vaccine is very effective at preventing infections. 1 The tetanus toxoid-conjugated Hib capsular polysaccharide vaccine is more immunogenic than the unconjugated capsular polysaccharide vaccine, and induces protective antibodies in 85% of allograft recipients including IgG2-deficient patients. 29 Barra et al 29 showed that between 4 and 18 months after BMT, the response to the conjugate vaccine did not correlate with GVHD, immunosuppressive therapy or time of vaccination. Beyond 18 months from BMT, response correlated with time (increasing efficacy with longer time intervals). 29 This may have been due to more complete immune reconstitution with the passage of time but no data were available to correlate immune status with response.
Guinan et al 30 reported that conjugate Hib vaccination at 12 and 24 months after BMT resulted in the development of protective antibodies 80% of the time compared with 50% for patients vaccinated only at 24 months. 30 Parkkali et al 31 randomized 45 adult allogeneic BMT recipients to receive Hib-DT conjugate vaccine at 6 or 18 months. Serologic responses a month after vaccination were poor but comparable in both groups. These observations suggest that multiple doses are essential.
Donor and recipient immunization with the Hib-conjugated vaccine before BMT resulted in higher antibody concentrations in patients as early as 3 months after BMT compared with immunization of patients after BMT. 32 Higher antibody levels in the early stages post-transplant could potentially decrease the incidence of respiratory tract infections in patients with lung disease or chronic GVHD.
Chan et al 22 compared Hib vaccination at 3, 6, 12 and 24 months among 17 autologous BMT and 10 autologous PBSCT recipients. Anti-Hib IgG antibody levels were significantly higher in blood cell recipients compared with marrow recipients before and after the 24 month dose. Protective anti-Hib antibody levels were seen earlier in blood cell recipients. This was presumably due to faster and more complete immune reconstitution with PBSCT.
In a separate study, 33 the same group reported that among autologous BMT recipients, Hib immunization prior to the marrow harvest resulted in higher Hib antibody concentrations during the first 2 years after BMT.
Hepatitis B
While the risk of hepatitis B virus (HBV) infection is not significant in regions with a low virus prevalence, the risk and morbidity of the infection in high-prevalence areas is considerable. The risk of infection may be high in highprevalence areas in the early post-transplant phase due to transfusion requirements.
Pretransplant HBV vaccination of donors can result in adoptive transfer of protective immunity to the recipient which may be useful in the early stages after transplantation. 4, 34 Wimperis et al 4 showed that immunization of the donor alone resulted in transfer of an antibody response to the recipient after T cell-depleted BMT, whereas immunization of donor as well as recipient resulted in a higher antibody response of a longer duration. Ilan et al 34 confirmed that pretransplant donor immunization could result in adoptive transfer of anti-HBV immunity to non-immune BMT recipients.
Resolution of the HBV carrier state and chronic hepatitis B can occur after allogeneic BMT from immune (anti-Hbs antibody-positive) donors. [35] [36] [37] [38] However, donor vaccination may not always be adequate to eradicate HBV in the recipient, 39 and in fact, reactivation of the virus with fatal liver failure has been described despite an allograft from an HBV-immune donor. 40 Li Volti et al 41 administered two doses of the HBV vaccine to 20 patients with homozygous ␤-thalassemia 18-24 months after allogeneic BMT. Thirteen had been successfully immunized 5-7 years before BMT, whereas seven had naturally acquired immunity following HBV infection in childhood. The loss of immunity after BMT was significantly more in vaccinated patients than among those who had acquired immunity naturally. However, after the administration of two doses of HBV vaccine, all patients in both groups developed protective levels of anti-Hbs antibodies. The geometric mean of anti-Hbs titers increased more significantly in patients who had acquired natural immunity than in patients who had been vaccinated in the past.
Nagler et al 42 reported that approximately two-thirds of autograft recipients vaccinated peritransplant developed low-titer antibody responses which could have been protective against hepatitis B-associated complications in the post-transplant phase.
These data suggest that multiple doses of hepatitis B vaccine are useful in non-immune patients or in those being allografted from non-immune donors, and that donor vaccination pretransplant under appropriate circumstances could also be beneficial. 28 
Influenza
The influenza virus continues to cause annual epidemics of respiratory diseases. Transplant recipients can acquire influenza infections during community epidemics, 43, 44 and secondary bacterial infections including pneumonia may have serious consequences. 44 Influenza vaccination within the first 6 months following BMT has been found to be ineffective. 45 However, in patients receiving the vaccine 2 or more years after BMT, efficacy has been found to be similar to that described in non-immunocompromised hosts, 45 with a positive correlation between longer transplant-immunization interval and seroconversion. Patients with chronic GVHD responded well to two of the virus strains and poorly to one.
It is also worthwhile vaccinating household contacts of transplant recipients to prevent transmission of influenza through them to patients; especially for patients who are still in the early post-transplant phase and are unlikely to mount an immune response themselves.
Measles
A substantial proportion of allograft recipients and some autograft recipients, especially children, lose immunity to measles over a period of time. 3, 7, 46, 47 Measles is an important pathogen in developing countries, 48 but apart from occasional outbreaks, it is not a problem elsewhere because of immunization. Although severe measles can occur in immunocompromised patients, there are few reports of measles following transplantation. 49 The live, attenuated trivalent measles-mumps-rubella vaccine has been administered safely to non-immunocompromised allograft recipients more than 2 years after BMT with seroconversion, 7, 50 and in autografted children. 46 Pauksen et al 51 measured measles IgG antibodies and T cell response to measles virus antigen in 60 allograft and 59 allograft recipients. The T cell response was significantly higher among seropositive than seronegative patients after autologous as well as allogeneic BMT. Seronegative children who received the measles vaccine after allogeneic BMT had a significantly higher T cell response than seronegative non-vaccinated children. No significant difference was seen in the T cell response among seronegative children vaccinated or not vaccinated after autografting. This suggested that most transplanted patients who lost measles IgG antibodies also lost a T cell response, but regained the T cell response upon seroconversion after vaccination.
In a further study of seronegative autograft recipients who were revaccinated post-transplant, Pauksen et al 52 found that a pre-existing T cell response correlated with an impaired B cell response, while pre-existing low-level IgG antibodies had no significant influence on the IgG titer rise. A sustained T cell response to measles antigen before revaccination may thus be a possible explanation for measles vaccine failure in transplanted patients. 49 Preferential Th1 stimulation and increase in interferon-production after measles vaccination may lead to a reduction in the humoral immune response which may explain the negative correlation between antibody production and T cell reativity prior to vaccination. 53 This potential mechanism for vaccination failure in transplanted patients has not been studied for other diseases.
Measles vaccination is not generally recommended for all transplant recipients, and should be considered on an individual basis for patients from high-prevalence geographic areas or where the risk for measles is increased. 12 
Mumps
As with measles, a large number of allograft and autograft recipients lose immunity to mumps.
7,46,47 Mumps has not been described to be a problem in transplanted patients. The attenuated trivalent measles-mumps-rubella vaccine has been administered to non-immunocompromised allograft recipients beyond 2 years from BMT with seroconversion, 7, 50 and in autografted children.
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Mumps vaccine is not recommended for all BMT recipients, 12 and should generally be administered only to children.
Pertussis
This vaccine is not routinely administered to individuals over the age of 6-7 years, and no systematic data are available on its use after transplantation. It would be reasonable to administer the DPT vaccine instead of the DT vaccine in young children (Table 3) .
Pneumococcus
Functional hyposplenism is a consequence of total body irradiation and chronic GVHD. Although pneumococcal infections are mainly a problem in patients with chronic GVHD 9 because of their inability to mount an antibody response to the pneumococcal polysaccharide antigen, 54 other patients can also be affected. Splenectomized patients and those autografted for Hodgkin disease and myeloma may be particularly at risk. A number of studies have evaluated pneumococcal vaccination in transplant recipients.
In a study of the 14-valent pneumococcal vaccine in allograft recipients. Winston et al 55 found that both pre-and post-immunization antibody levels for all serotypes were lower in patients compared with normal subjects. Antibody responses of patients not on steroids and vaccinated more than 7 months after BMT improved with time.
Lortan et al 56 found that the titers of specific IgG, IgG1 and IgG2 pneumococcal antibodies fell significantly after allogeneic BMT in children. Their response to 23-valent vaccine a year or longer after BMT was not significantly different from normal controls except for poorer IgG2 response. However, patients did not achieve a high specific antibody titer in any immunoglobulin subclass because of lower preimmunization antibody levels. The preimmunization antibody levels and response to immunization were not affected by previous splenectomy or chronic GVHD. Immunization of donors before the marrow harvest did not influence the levels of specific antibody a year or more after BMT.
Molrine et al 32 also found that pretransplant donor vaccination did not affect the recipient's antibody response to post-transplant vaccination. They also administered a polysaccharide pneumococcal vaccine 18 and 24 months after autograft with or without a dose of the vaccine prior to the marrow harvest, and found that pretransplant vaccination had no impact on the eventual antibody titers. 33 Avanzini et al 57 found that all children vaccinated more than 2 years after autologous or allogeneic BMT responded to pneumococcal polysaccharide compared with only 20-50% of those vaccinated within 2 years. Although chronic GVHD influenced the response rate in univariate analysis, only the time between BMT and immunization was significant in multivariate analysis. The observation of improving response to pneumococcal vaccination with increasing time after transplantation seems to suggest that B cell ontogeny follows a sequential program in which polysaccharide antigens are amongst the last to evoke antibody responses.
Hammarstrom et al 58 found that over the first year after BMT, pneumococcal antibody levels decreased in most allograft recipients, but not in autograft recipients. None of the patients with chronic GVHD showed normal levels of antibodies at 1 year. Of the patients who lost immunity after BMT and were vaccinated with a polyvalent pneumococcal vaccine, roughly one-third showed a rise in IgG2 antibodies, one-third an increase in IgG1, and one-third did not respond at all. None of the patients with chronic GVHD showed an increase in IgG2 antibodies and three-quarters did not respond at all.
Parkkali et al 31 randomized 45 adult allograft recipients to receive pneumococcal polysaccharide vaccine at 8 or 20 months. Serologic responses a month after vaccination were poor but comparable in both groups, except that doubling of antibody concentration to the most immunogenic pneumococcal serotype (serotype 3) occurred more frequently among patients vaccinated at 20 months. In the latter group, the antibody responses elicited by serotypes 3 and 19F correlated with the concentrations of the corresponding antibodies in the donor.
The covalent linkage of a polysaccharide antigen to a protein such as tetanus or diphtheria toxoid results in a more immunogenic molecule which evokes a T cell-dependent immune response which is stronger in an immature immune system and is longer lasting. This could be more useful than the poorly immunogenic pneumococcal polysaccharide vaccine. A heptavalent pneumococcal polysaccharide-protein conjugate vaccine has been found to be as immunogenic as the 23-valent polysaccharide vaccine in allografted patients. 59 The 23-valent polysaccharide vaccine, apart from being poorly immunogenic, also does not cover 20% of the commonly encountered pathogenic pneumococcal strains -and immunized individuals remain susceptible to them. Additionally, as data shown above demonstrate, immune responses are impaired in patients with chronic GVHD. Life-long prophylactic penicillin V (250 mg twice daily orally) is therefore recommended for all patients who have had TBI prior to an autograft or allograft, patients with chronic GVHD and splenectomized patients. 9, 12 Erythromycin (250 mg twice daily orally) or clarithromycin (250 mg once daily orally) may be used in penicillin-allergic subjects.
Poliovirus
Poliomyelitis continues to remain a serious problem in a number of developing contries, and sporadic outbreaks are seen in developed countries in non-immunized individuals. 60, 61 Immunity to polio is gradually lost after BMT. 25, [62] [63] [64] Englehard et al 62 showed that 68-80% of allogeneic BMT recipients had protective antibodies against the three serotypes of poliovirus 6-96 months after BMT compared with 92-96% before BMT, and the titers were significantly lower than pretransplant. Immunization with two doses of inactivated polio vaccine 6-96 months after BMT resulted in increased antibody titers in all patients. Presence of GVHD, pretransplant polio antibody titers, age, and the type of graft affected response to the vaccine, but the time from BMT to vaccination did not.
Ljungman et al 63 found that although almost 70% of allograft recipients were seropositive to all poliovirus types a year after BMT, at least a four-fold decrease in antibody level was seen in roughly half the patients from their pretransplant levels. Half of the patients receiving three inactivated polio vaccine doses responded, and the presence of chronic GVHD did not affect the response.
Parkkali et al 64 randomized 45 adult allograft recipients to receive inactivated polio vaccine at 6, 8 and 14 months, or at 18, 20 and 26 months after BMT. While both schedules were found to be equally immunogenic, the proportion of patients with protective antibody titers prior to the first dose was greater for the early group (95% prior to the 6-month dose) than for the late group (67% prior to the 18-month dose). Acute GVHD accelerated the decline of antibody titers prior to vaccination but had no influence on response to the vaccine. Chronic GVHD neither influenced the decline of antibody titers nor the response to vaccination.
Pauksen et al 65 found that around 20% of autograft recipients had lost antibodies to at least one type of poliovirus a year after autografting. 65 This time-dependent decrease in antibody titers continued in unvaccinated patients in the second and third years. A high proportion of seronegative patients reimmunized with three doses of the inactivated vaccine responded. 65 The inactivated polio vaccine has also been successfully administered to pediatric patients autografted using bone marrow depleted of B lymphocytes, 5 and in patients allografted for thalassemia who did not have chronic GVHD. 27 There are no published data on the use of the oral vaccine in non-immuncompromised transplant recipients or their household contacts. The oral vaccine should be certainly avoided in immunocompromised transplant patients (Table  1) as well as their houshold contacts.
Rubella
As with measles and mumps, a number of allograft and autograft recipients lose immunity to rubella. 7, 46, 47 Although rubella is not a significant infection in transplant recipients, successful pregnancies have been reported in transplant recipients. 66, 67 The offspring of these women could be at risk of the congential rubella syndrome, and it would therefore be advisable to revaccinate women with child-bearing potential. The attenuated trivalent measlesmumps-rubella vaccine has been administered to nonimmuncompromised patients more than 2 years after allogeneic BMT with development of immunity to rubella, 7, 50 and in autografted children. 46 
Tetanus toxoid
There is evidence to suggest that tetanus toxoid-specific immunity can be transferred by allogeneic transplantation, and can persist in long-term survivors without immediate pretransplant toxoid administration to donors or to recipients pre-or post-transplant. 2, 6 Contrasting observations were made by Ljungman et al 8 who found that half of the patients who were immune to tetanus before BMT had lost their immunity by 1 year after BMT, and all the patients who were not reimmunized with tetanus toxoid were seronegative at 2 years. Response rates were relatively poor and loss of immunity common in patients immunized with one or two doses of toxoid after BMT. However, primary immunization with three doses of toxoid resulted in 100% response and sustained immunity. 8 Among patients receiving tetanus toxoid 3, 6 and 12 months afer T cell-depleted BMT, only those who had been immunized pretransplant along with their donors responded effectively. 68 Tetanus toxoid administration resulted in adequate immune response in pediatric patients autografted using bone marrow depleted of B lymphocytes, 5 and in thalassemic patients who did not have chronic GVHD. 27 Parkkali et al 69 randomized 45 adult allograft recipients to receive tetanus toxoid at 6, 8 and 14 months, or at 18, 20 and 26 months. While both schedules were found to be equally immunogenic with all patients achieving a protective antibody concentration, the proportion of patients with protective antibody titers prior to the first dose was greater for the early group (90% prior to the 6-month dose) than for the late group (70% prior to the 18-month dose). In the late group, recipient antibody responses after the first and second vaccine doses correlated with donor antibody level suggesting that donor immunity against tetanus may influence recipient responses to tetanus toxoid.
Chan et al 22 administered tetanus toxoid at 3, 6, 12 and 24 months to 17 autologous BMT and 10 autologous PBSCT recipients. Anti-tetanus toxoid IgG antibody levels were significantly higher in PBSCT recipients compared with BMT recipients before and after the 24 month dose. These results suggest enhanced recovery of functional humoral immunity in PBSCT recipients.
Gerritsen et al 70 studied response to tetanus toxoid in allografted children and autografted or T-depleted allografted adults. In children, who were routinely reimmunized early after BMT, the antibody response was quantitatively superior to that in adults who were not reimmunized early. In the majority of patients, the time required to reach peak antibody levels was prolonged and the number of tetanus toxoid-specific B cell clones was markedly decreased in comparison with controls. Unlike the controls, production of relatively high concentrations of homogeneous antibodies against a heterogeneous background was seen in BMT recipients. These abnormalities were present up to 10 years after BMT, irrespective of age, type of transplant or reimmunization schedule. Their data indicate that routine reimmunication early after BMT may improve the specific immune response, but because of dysregulated antibody production, long-lasting qualitative defects may be present even after normalization of antibody titers.
They also tested 98 pediatric allograft recipients for the potential presence of homogeneous IgG with specificity towards a panel of antigens including vaccines, herpesvirus antigens, and other auto-and allo-antigens. 71 The majority of sera were unreactive against this panel of antigens, but antigen specificity of the homogeneous IgG to tetanus toxoid could be demonstrated after vaccination with tetanus toxoid in four patients. 71 The significance of this finding is unknown.
Varicella
Varicella zoster virus (VZV) reactivation (shingles) is a significant problem after transplantation. Prevention of reactivation requires prolonged suppressive therapy with acyclovir. This delays reconstitution of VZV-specific immunity resulting in delayed reactivation after acyclovir is stopped. 72 Data on the usefulness of varicella vaccination after transplantation are limited. 73, 74 Sauerbrei et al 73 administered a live attenuated VZV vaccine to 15 patients 12-23 months after BMT. The vaccine was well tolerated without adverse reactions. Chickenpox or herpes zoster were not observed for up to 2 years after immunization. Eight of nine seronegative patients seroconverted, and in six virus-specific IgG could be detected 2 years later. These data are somewhat difficult to interpret since patients were vaccinated beyond the period when VZV vaccination is usually seen.
Transmission of the attenuated varicella vaccine virus from an immunized infant to his mother as been reported. 75 Therefore, it is possible that administering the live vaccine in the early period after transplantation, when the benefits would be maximal, may give rise to a clinical picture of primary infection or reactivation and may be dangerous.
Redman et al 74 randomized 75 BMT recipients to receive the live attenuated vaccine which was heat-inactivated specifically for the study or to no intervention. Among patients given a single dose of the vaccine a month after BMT, clinical disease was unaltered compared with unvaccinated patients. However, among patients vaccinated at 1, 2 and 3 months post-transplant, the clinical severity of VZV reactivation was significantly less. Thus the process of inactivation of the vaccine virus did not eliminate the immunogenicity of the vaccine and apparently conferred some protection -an interesting observation which requires confirmation.
The live attenuated vaccine (without heat treatment) may have to be used with caution or avoided in household contacts of immunocompromised transplant patients, or if contacts are vaccinated, patients should receive acyclovir prophylaxis. A prior history of chickenpox, ie wild-type VZV infection, may not protect against vaccine-type VZV.
Other vaccines
There are no data on the use of the inactivated hepatitis A vaccine in transplant recipients. However, considering the efficacy of the vaccine and the risk of hepatitis A among travelers to endemic areas, 1 it is possible that its use will become commonplace. Similarly, the usefulness of the meningococcal vaccine requires further study.
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Measurement of the immune response to vaccines
Adequacy of the immune response to a vaccine is frequently measured by the serum level of the specific antibody. Although seroconversion does indicate an immune response, it does not necessarily signify protection.
1 Antibody development correlates with clinical protection after some vaccines (eg measles and rubella). Antibody development does not indicate immunity after some vaccines but is associated with some protection (eg serum vibriocidal antibodies in cholera). In some cases (eg tetanus), the antibody titer is crucial and protection is indicated by the level of the circulating antibody. Functional capacity of pneumococcal vaccine may be assessed by measuring the antibodymediated opsonic activity against S. pneumoniae. 76 While routine determination of antibody titers prior to vaccination is not recommended in all transplant recipients, 12 post-vaccination determination of antibody levels is useful to monitor antibody response and protection, and assess the need for additional doses of the vaccine. Studies are needed to determine the relationship between immune reconstitution and the extent of response to immunization.
Adoptive transfer of protective immunity
Although immunity can be transferred adoptively from the donor to the recipient through an allograft, the durability of this immune response is uncertain, and most data in clinical practice suggest a fall in the antibody titers over a period of time after BMT. [2] [3] [4] [5] [6] [7] [8] Therefore, adoptive transfer of immunity with allogeneic marrow transplantation probably does not overcome the need for routine reimmunization in the majority of cases. Adoptive transfer of immunity is still investigational, and has no place in routine clinical practice at the moment.
Shepherd and Noelle 77 showed in a murine model, that while adoptive transfer of immune splenic B cells or immune peripheral blood mononuclear cells effectively transferred antigen-specific IgG1 antibody responses of donor origin to recipients, marrow from immune animals did not transfer a memory response. They suggested that the transfer of immunological memory observed in human BMT may be a consequence of peripheral blood contamination of the harvested donor marrow. The number of B cells in blood stem cell harvests from healthy donors is up to 20 times higher than marrow. 78 Therefore it is possible that peripheral blood stem cell allografts may adoptively transfer immunity more effectively and this may be much more durable. However, no data are currently available to suggest that routine immunization after PBSCT is unnecessary.
Serious infections are common in the early phase following allogeneic transplantation. Augmentation of immunity to some of the common pathogenic organisms by adoptive transfer could conceivably reduce infection-related mortality and improve outcome. However, adoptive transfer of antibody responses is possible only for recall antigens. Transfer of responses to priming antigens, which would broaden the range of organisms against which patients can be protected, is not successful. 79 Gottlieb et al 80 immunized marrow donors and/or recipients pretransplant with a polyvalent pseudomonas O-polysaccharide-toxin A conjugate vaccine. When either donor or recipient alone was vaccinated, no increase in specific antibody titers was observed in the recipient post-transplant. However, when both donor and recipient were vaccinated before BMT, antibody titers increased to levels shown to be protective in animal models of gram-negative sepsis. 80 The requirement for both donor and recipient immunization 79, 80 reflects the need for primed donor B lymphocytes in the marrow inoculum to be transferred into an antigen-containing environment for maximum B cell proliferation and antibody production.
Specific cell-mediated immunotherapy, comprising the adoptive transfer of virus antigen-specific cytotoxic T lymphocytes from the donor, has been shown to be effective in cytomegalovirus 81 and Epstein-Barr virus-induced 82 lymphoproliferative disease in allograft recipients. A detailed discussion of this technique is beyond the scope of this review.
Passive immunization
The indications for passive immunization with specific immunoglobulin preparations in transplanted patients are similar to those in otherwise healthy individuals, and are beyond the scope of this review. 1, 83 Administration of highdose intravenous immunoglobulin, a form of passive immunization, is commonly employed for up to 4 months post-transplant (especially allogeneic) for its beneficial effects on infections and GVHD. 84 However, there is evidence that prolonged administration of immunoglobulin (for 1 year) is associated with delayed immune reconsti-tution and an increased incidence of infections after discontinuation of immunoglobulin. 85 While reimmunizing transplant recipients, possible interference of immunoglobulin administration with response to vaccination must be borne in mind. Response to the measles-mumps-rubella vaccine in healthy children has been shown to be suboptimal for 3 months after the administration of 80 mg/kg of immunoglobulin. 86 A similar observation has been made in adult recipients of tetanusdiphtheria vaccine along with tetanus immune globulin, 87 but to a much smaller extent.
